Inactive Instrument

News ContraVir Pharmaceuticals Inc Nasdaq

Equities

US21234W1036

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell	Mar. 06	AQ
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	Mar. 06	CI
Hepion Pharmaceuticals, Inc. Announces Board Changes	Feb. 20	CI
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	Feb. 16	AQ
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	Feb. 07	CI
Hepion Pharmaceuticals to Present at NASH-TAG 2024	Jan. 03	AQ
North American Morning Briefing : Futures Pause -2-	Dec. 08	DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	Dec. 07	CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	Dec. 07	MT
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	Dec. 07	AQ
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director	Dec. 07	CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes	Dec. 07	CI
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit	Nov. 28	AQ
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease	Nov. 13	AQ
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	Nov. 13	CI
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	Nov. 10	AQ
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model	23-10-25	AQ
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	23-10-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ContraVir Pharmaceuticals Inc Nasdaq

Equities

US21234W1036

Summary

Filters